Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
5
Recruiting, industry sponsors, Rare and genetic disease, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
5 trials
Showing 1 to 5, recently updated first.
BioMarin PharmaceuticalBioMarin (BMRN)
NCT07477691 · 12 participants (planned) · Start May 29, 2026 · Primary completion Sep 30, 2027
Drug: Pegvaliase; Methotrexate · For: Phenylketonuria
Sites: Los Angeles, California; Aurora, Colorado; Tampa, Florida · 12 sites in all
Swedish Orphan BiovitrumIndustry
NCT07746895 · 150 participants (planned) · Start Aug 5, 2026 · Primary completion Dec 31, 2031
Drug: Pegcetacoplan · For: C3 Glomerulopathy (C3G); Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Sites: Kingswood, Australia; Woolloongabba, Australia; Graz, Austria · 101 sites in all
ShireTakeda (TAK)
NCT05067868 · 5 participants (planned) · Start Nov 1, 2022 · Primary completion Oct 31, 2027
Drug: Replagal · For: Fabry Disease
Sites: Kolkata, India; New Delhi, India · 3 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07142343 · 5 participants (planned) · Start Mar 19, 2026 · Primary completion Feb 12, 2030
Drug: Pozelimab · For: CHAPLE Disease
Sites: Istanbul, Turkey (Türkiye)
- China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPDRecruiting
Genzyme, a Sanofi CompanySanofi (SNY)
NCT06666413 · 13 participants (planned) · Start May 7, 2025 · Primary completion May 2, 2028
Drug: Avalglucosidase alfa · For: Glycogen Storage Disease Type II; Pompe's Disease
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.